For the quarter ending 2025-09-30, SNTI made $17,337K in revenue. -$18,126K in net income. Net profit margin of -104.55%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
| Impairment of long-lived assets | - | - | 313 | - |
| Research and development | 10,516 | 10,029 | 8,655 | 9,151 |
| General and administrative | 6,432 | 6,769 | 6,247 | 4,205 |
| Total operating expenses | 16,948 | 16,798 | 15,215 | 13,356 |
| Loss from operations | -16,948 | -16,798 | -15,215 | -13,356 |
| Genefab sublease income - related party | - | - | 1,657 | 1,587 |
| Change in fair value | - | - | -15,447 | 324 |
| Interest income | 166 | 270 | 150 | 236 |
| Genefab sublease income - related party-Related Party | - | 1,586 | - | - |
| Genefab sublease income (expense) - related party-Related Party | -1,567 | - | - | - |
| Other income (expense), net | 223 | 209 | -11 | 6 |
| Change in fair value-Gene Fab Option | 0 | 0 | - | - |
| Change in fair value-Gene Fab Economic Share | 0 | 0 | - | - |
| Change in fair value-Gene Fab Note Receivable | 0 | 0 | - | - |
| Total other income (expense), net | -1,178 | 2,065 | -13,651 | 2,153 |
| Net loss from continuing operations | - | - | -28,866 | -11,203 |
| Net loss | -18,126 | -14,733 | -28,866 | -11,203 |
| Comprehensive loss | - | - | -28,866 | -11,203 |
| Net loss per share, basic (in dollars per share) | -0.69 | -0.56 | -6.31 | -2.45 |
| Net loss per share, diluted (in dollars per share) | -0.69 | -0.56 | -6.31 | -2.45 |
| Weighted-average number of shares used in computing net loss per share, basic (in shares) | 26,228,274 | 26,081,273 | 4,577,122 | 4,572,010 |
| Weighted-average number of shares used in computing net loss per share, diluted (in shares) | 26,228,274 | 26,081,273 | 4,577,122 | 4,572,010 |
Senti Biosciences, Inc. (SNTI)
Senti Biosciences, Inc. (SNTI)